E-Paper
Sun to stop selling cancer drug Oxaliplatin in US from July
Sun Pharmaceutical Industries Saturday said it will stop selling generic Oxaliplatin, a cancer treatment drug, in the US after June 30, following an order by a New Jersey court.
Sun Pharmaceutical Industries Saturday said it will stop selling generic Oxaliplatin, a cancer treatment drug, in the US after June 30, following an order by a New Jersey court.
"The US District Court for the District of New Jersey denied Sun Pharma's motion to suspend the court's order dated April 22, 2010, which entered a consent judgement and order having the effect of enjoining Sun Pharma from selling a generic Oxaliplatin product," the Mumbai-based company said in a statement.
Accordingly, Sun Pharma will stop selling the product after June 30, 2010, it added.
Sun Pharma had appealed the court order and intends to litigate the matter before the United States Court of Appeals for the Federal Circuit, it added.
The company asserted that the grounds for appeal are strong and plans to contest the entry of the Consent Judgement and Order vigorously.
"On receipt of a favourable judgement from the appellate court, Sun plans to re-initiate the sales of the product," the statement added.
Oxaliplatin is a generic version of Sanofi Aventis' patented Eloxatin, which is used in chemotherapy.
Sanofi Aventis had filed patent litigation against generic manufacturers, including Sun Pharma, to cease sales of their infringing products in the US.
